Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 2 1Phase 1/2 1

Status

Completed 4Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 5OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Breast 6Genitourinary 1

Conditions

Breast Neoplasms 6Neoplasms 3Neoplasm Metastasis 3Neuroendocrine Tumors 2Neuroectodermal Tumors, Primitive 2Glioblastoma 2Carcinoma, Renal Cell 2Uterine Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Perivascular Epithelioid Cell Neoplasms 1Pancreatic Neoplasms 1Malignant Solid Tumour 1Leukemia, Myeloid, Acute 1Kidney Neoplasms 1Hamartoma Syndrome, Multiple 1Gliosarcoma 1Endometrial Neoplasms 1Castration-resistant Prostate Cancer 1Castrate-resistant Prostate Cancer 1Carcinoma, Transitional Cell 1Breast Diseases 1Brain Neoplasms 1Angiomyolipoma 1Advanced Solid Tumor 1

Interventions

Trastuzumab 625Paclitaxel 576Cyclophosphamide 555Docetaxel 484Capecitabine 401Letrozole 376Fulvestrant 326Doxorubicin 294Carboplatin 279Tamoxifen 275Anastrozole 243exemestane 228Radiotherapy 218Epirubicin 211Bevacizumab 196palbociclib 189pertuzumab 184Vinorelbine 167Lapatinib 167Gemcitabine 166pembrolizumab 162Surveys and Questionnaires 138Exercise 136Magnetic Resonance Spectroscopy 123Fluorouracil 119Blood Specimen Collection 118eribulin 117Albumin-Bound Paclitaxel 117Drug Therapy 111130-nm albumin-bound paclitaxel 111

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Breast Neoplasms × dactolisib × Clear all
NCT01482156 2020-12-21

Dose Finding Study of RAD001 (Everolimus, Afinitor®) in Combination With BEZ235 in Patients With Advanced Solid Tumors

Novartis

Phase 1 Completed
46 enrolled
BreastGenitourinary

Breast Neoplasms, Carcinoma, Renal Cell

NCT00620594 2020-12-09

A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer

Novartis

Phase 1 Completed
183 enrolled
Breast

Breast Diseases, Breast Neoplasms, Hamartoma Syndrome, Multiple, Neoplasms

NCT01471847 2020-12-09

A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab

Novartis

Phase 1 Completed
5 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01495247 2020-12-08

Phase Ib/II Trial of BEZ235 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer

Novartis

Phase 1/2 Terminated
18 enrolled
Breast

Breast Neoplasms, Neoplasm Metastasis

NCT01248494 2016-07-25

PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer

Vanderbilt-Ingram Cancer Center

Phase 1 Completed
72 enrolled
Breast

Breast Neoplasms

NCT01288092 2012-06-07

BEZ235 Trial in Patients With HER2-(Human Epidermal Growth Factor Receptor 2 Negative) /HR+ (Hormonal Receptor Positive) Metastatic Breast Cancer

Novartis

Phase 2 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡